Cantor Fitzgerald Comments on Immunovant FY2026 Earnings

Immunovant, Inc. (NASDAQ:IMVT) – Investment analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Immunovant in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen expects that the company will earn ($2.92) per share for the year. The consensus estimate for Immunovant’s current full-year earnings is ($2.75) per share.

Immunovant (NASDAQ:IMVT) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). During the same period in the prior year, the company earned ($0.45) EPS.

A number of other research firms have also recently issued reports on IMVT. Raymond James reiterated an “outperform” rating and issued a $36.00 target price on shares of Immunovant in a research report on Thursday, October 10th. Oppenheimer boosted their target price on shares of Immunovant from $47.00 to $53.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 9th. Wolfe Research cut Immunovant from an “outperform” rating to a “peer perform” rating in a research note on Friday, January 3rd. HC Wainwright restated a “buy” rating and set a $51.00 price objective on shares of Immunovant in a research report on Friday, November 8th. Finally, Bank of America lowered their target price on Immunovant from $48.00 to $45.00 and set a “buy” rating for the company in a report on Wednesday, January 15th. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $47.00.

Immunovant Stock Performance

Shares of IMVT stock opened at $23.57 on Thursday. Immunovant has a fifty-two week low of $22.41 and a fifty-two week high of $40.12. The company has a market cap of $3.46 billion, a PE ratio of -10.67 and a beta of 0.66. The stock’s fifty day moving average price is $26.02 and its two-hundred day moving average price is $28.42.

Institutional Trading of Immunovant

Several hedge funds have recently modified their holdings of the stock. Victory Capital Management Inc. increased its stake in Immunovant by 7.4% in the third quarter. Victory Capital Management Inc. now owns 335,360 shares of the company’s stock valued at $9,561,000 after purchasing an additional 22,990 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Immunovant by 19.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 552,430 shares of the company’s stock valued at $15,750,000 after buying an additional 91,259 shares in the last quarter. Principal Financial Group Inc. raised its stake in Immunovant by 69.9% during the 3rd quarter. Principal Financial Group Inc. now owns 951,124 shares of the company’s stock worth $27,117,000 after buying an additional 391,436 shares during the period. State Street Corp boosted its holdings in Immunovant by 11.2% in the third quarter. State Street Corp now owns 3,022,342 shares of the company’s stock worth $86,167,000 after acquiring an additional 303,386 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Immunovant by 6.9% in the third quarter. Geode Capital Management LLC now owns 1,510,926 shares of the company’s stock valued at $43,085,000 after acquiring an additional 96,924 shares during the period. Institutional investors own 47.08% of the company’s stock.

Insider Buying and Selling at Immunovant

In related news, insider Mark S. Levine sold 3,650 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $25.45, for a total transaction of $92,892.50. Following the completion of the sale, the insider now owns 319,228 shares of the company’s stock, valued at $8,124,352.60. This trade represents a 1.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Peter Salzmann sold 8,767 shares of Immunovant stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $23.83, for a total value of $208,917.61. Following the completion of the sale, the chief executive officer now owns 964,225 shares of the company’s stock, valued at approximately $22,977,481.75. The trade was a 0.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 68,040 shares of company stock valued at $1,697,399. 5.90% of the stock is currently owned by company insiders.

About Immunovant

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.